Dr. Boris Farber and his team are not merely participating in personalized medicine—they are pioneering its parallel, independent development: Self-Personalized Medicine (SPM). This new direction is embodied in next-generation dynamic, self-adaptive, and self-assembled medical drugs with variable structure and design. This platform technology resolves the core contradiction facing modern healthcare: how to achieve mass-production scalability and cost-efficiency while delivering truly customized, single-patient efficacy.

Leveraging advanced mathematical modeling, artificial intelligence (AI), and the application of the Theory of Inventive Problem Solving (TRIZ) to drug design—grounded in Patterns of System Evolution—Dr. Farber has dedicated his career to developing therapeutic Platforms that adapt dynamically to individual patient needs. His work delivers highly effective, tailored treatments for some of the world’s most challenging medical conditions.

The Dynamic Platform: Self-Personalizing in the Human Body

With a distinguished career spanning over four decades, Dr. Farber and his team have developed a new class of Dynamic Drugs. This platform is engineered to self-personalize within each patient’s unique biological environment, addressing a critical unmet need in modern healthcare. These drugs are fundamentally “quasi-living,” designed to sense and respond to the patient's pathology in real-time.His innovative research integrates advanced mathematical modeling, bioengineering, and TRIZ methodology to produce these dynamic, self-adjusting therapeutics. His contributions include hundreds of inventions, numerous scientific publications, and international awards, establishing him as a visionary leader in translating scientific discovery into powerful, high-impact medical solutions.

Educational Background: An Unparalleled Interdisciplinary Foundation

Dr. Farber holds Triple PhDs in Biomedical Systems, Robotic Systems, and Control in Medical and Biological Systems, with a specialization in Mathematical and Computer Modeling, and a Full Professor Diploma. This depth of interdisciplinary expertise is enhanced by professional diplomas in Organic and Analytical Chemistry, Pharmaceutical Chemistry, Pharmacognosy, and drug development, as well as focused, specialized study in AI in Drug Design, including programs at MIT (AI in Drug Design), Harvard Medical School (AI in Healthcare), and Cambridge (Precision Medicine), Applied Math. This unparalleled educational foundation directly drives his transformative contributions to healthcare.

Professional Achievements: From TRIZ Principle to Clinical Breakthrough

ODr. Farber holds the unique distinction of being the sole TRIZ Master who applies TRIZ with his Team to all projects in pharmaceuticals that they have been developing. For over 35 years, he has applied TRIZ principles to transform conventional medicines into self-personalized ones. The foundation of his breakthrough methodology stems from core concepts for applying TRIZ to drug design, developed and refined over many years through direct, sustained discussions with Genrich Altshuller, the father of TRIZ. This collaboration provides a unique, first-principles approach that fundamentally separates the team's drug discovery process from conventional models. His pioneering work has led to the development of the first dynamic, self-adaptive “quasi-living” drugs, including: MoLRx for cancer treatment, Albuvir for viral infections, Adaptive Insulin, Dipasol for wound healing, the hemostatic agent Gemma, and many others. The MoLRx platform has demonstrated global scalability and achieved 100% survival in an MDR lung cancer preclinical model, based on grants for early research. Crucially, clinical data from terminal-stage volunteers treated with the MoLRx platform showed a marked reduction in metastatic carcinomas, with tumor size reduced by approximately half after the third treatment. These therapies adjust in real-time, demonstrating high preclinical efficacy and setting a new global standard in personalized medicine. Dr. Farber’s universal approach to developing nephroprotective drugs is a significant contribution, safeguarding kidneys from nephrotoxic medications without compromising efficacy. With over 220 patents granted globally—including 10 U.S. patents for dynamic drugs—and more than 500 scientific publications and books, his innovations span dynamic anticancer antisense microRNA, antiviral oligopeptides, stem cell growth stimulants, and antimicrobial formulations for multidrug-resistant strains. His influence also extends to applications in cosmetology and food science.

Leadership Roles

As CEO of TRIZ Biopharma Innovations LLC (New Jersey) and TRIZ Biopharma International LLC (New York), Dr. Farber leads highly specialized interdisciplinary teams. These teams strategically merge AI-powered simulations with advanced TRIZ methodologies to achieve breakthroughs in drug design. As Principal Investigator on multiple projects, he has spearheaded innovations such as antisense oligo-RNAs for targeted cancer therapy and antiviral peptides with remarkable efficacy against different viral strains, all focused on addressing critical unmet needs in global healthcare.

Vision and Collaboration

Dr. Farber’s vision for the future of medicine is rooted in the synergistic power of dynamic drug design and artificial intelligence. With foundational experience in AI dating back nearly 40 years—including early work on expert systems for biomedical diagnostics and therapy—he is a leading voice in the convergence of these fields. Today, Dr. Farber emphasizes that only synergy of a combination few AI Platforms is the critical enabler in realizing the 3,500-year dream of truly personalized medicine. He actively values and welcomes collaboration with professionals in AI and drug design to advance these adaptive treatments and better meet individual patient needs globally.

Awards and Recognition

Dr. Farber’s contributions have earned him membership in nine prestigious scientific academies. He has received numerous accolades, including the Paul Ralph Ehrlich Medal, Otto Heinrich Warburg Medal, Nikola Tesla Gold Medal, and the European Academy for Natural Sciences Award for his advancements in TRIZ-based drug development. These honors reflect his relentless dedication to advancing healthcare through rigorous science and innovative problem-solving.

Conclusion

Dr. Farber’s TRIZ-based methodology, which fuses mathematical precision, adaptive treatments, and extensive AI experience, provides the pharmaceutical industry with truly groundbreaking approaches to addressing challenging diseases. Through his development of Self-Personalized Medicine, Dr. Farber’s unique approach continues to offer hope and healing to patients worldwide, defining and paving the way for a new era in global healthcare. https://www.youtube.com/watch?v=c9rfPmncy1U&t=76s

For a deeper exploration of his work in personalized medicine, see his presentation Dr. Farber’s unique approach continues to offer hope and healing to patients worldwide, paving the way for a new era in healthcare” https://www.youtube.com/watch?v=eO1D6ER3-RY

Memberships

• American Society for Pharmacology and Experimental Therapeutics
• American Society for Microbiology
• American Chemical Society
• Association for the Advancement of Artificial Intelligence
• American Mathematical Society

Works and publications:

https://www.linkedin.com/in/dr-boris-farber-0309b6121/

https://orcid.org/0000-0001-9166-1274

https://www.researchgate.net/profile/

https://www.scopus.com/authid/detail.uri?authorId=45561244000